Cited by 2,087Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Open access

Miller, Brian C., Sen, Debattama R., Al Abosy, Rose, Bi, Kevin, Virkud, Yamini V., LaFleur, Martin W., Yates, Kathleen B., Lako, Ana, Felt, Kristen, Naik, Girish S., Manos, Michael, Gjini, Evisa, Kuchroo, Juhi R., Ishizuka, Jeffrey J., Collier, Jenna L., Griffin, Gabriel K., Maleri, Seth, Comstock, Dawn E., Weiss, Sarah A., Brown, Flavian D., Panda, Arpit, Zimmer, Margaret D., Manguso, Robert T., Hodi, F. Stephen, Rodig, Scott J., Sharpe, Arlene H., Haining, W. Nicholas·2019·Nature Immunology

DOI 10.1038/s41590-019-0312-6PMC PMC6673650

Open this paper in CoChat — free account

Abstract

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8+ tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8+ TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8+ TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8+ TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8+ T cells might be an important component of improving the response to checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41590-019-0312-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citation
Control of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citation
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072

Show all 53 references

Sorted by citations

Items 601–700 of 1,002

SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
Hajaj, E., Eisenberg, G., Klein, S., Frankenburg, S., Merims, S., David, I. B., Eisenhaure, T., Henrickson, S. E., Villani, A., Hacohen, N., et al. (2020) · eLife · doi:10.7554/elife.52539 · Cited by 43
A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer
Liu, C., Gong, J., Yu, H., Liu, Q., Wang, S., & Wang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.544339 · Cited by 43
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 42
Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer
Komuro, H., Shinohara, S., Fukushima, Y., Demachi‐Okamura, A., Muraoka, D., Masago, K., Matsui, T., Sugita, Y., Takahashi, Y., Nishida, R., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007180 · Cited by 45
HMGB2 regulates the differentiation and stemness of exhausted CD8+ T cells during chronic viral infection and cancer
Neubert, E. N., DeRogatis, J. M., Lewis, S. A., Viramontes, K. M., Ortega, P., Henriquez, M. L., Buisson, R., Messaoudi, I., & Tinoco, R. (2023) · Nature Communications · doi:10.1038/s41467-023-41352-0 · Cited by 45
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Parra, E. R., Zhang, J., Duose, D. Y., Gonzalez‐Kozlova, E., Redman, M. W., Chen, H., Manyam, G. C., Kumar, G., Zhang, J., Song, X., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0251 · Cited by 43
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 49
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 49
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen, C., Liu, Y., & Cui, B. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1840254 · Cited by 43
Type 17 immunity promotes the exhaustion of CD8+ T cells in cancer
Kim, B. S., Kuen, D., Koh, C., Kim, H., Chang, S. H., Kim, S., Jeon, Y. K., Park, Y.-J., Choi, G., Kim, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002603 · Cited by 44
Role of the tumor immune microenvironment in tumor immunotherapy (Review)
Zhou, C., Liu, Q., Xiang, Y., Gou, X., & Li, W. (2021) · Oncology Letters · doi:10.3892/ol.2021.13171 · Cited by 42
Metabolites and Immune Response in Tumor Microenvironments
Cortellino, S., & Longo, V. D. (2023) · Cancers · doi:10.3390/cancers15153898 · Cited by 43
Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens
Schlabach, M. R., Lin, S., Collester, Z. R., Wrocklage, C., Shenker, S., Calnan, C., Xu, T., Gannon, H., Williams, L. J., Thompson, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163096 · Cited by 44
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia
Mazziotta, F., Biavati, L., Rimando, J. C., Rutella, S., Borcherding, N. C., Parbhoo, S., Mukhopadhyay, R., Chowdhury, S., Knaus, H. A., Valent, P., et al. (2024) · Blood · doi:10.1182/blood.2023021680 · Cited by 41
Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
Broomfield, B. J., Tan, C. W., Qin, R. Z., Abberger, H., Duckworth, B. C., Alvarado, C., Dalit, L., Lee, C. L., Mugan, R. S., Mazrad, Z. A. I., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241148 · Cited by 42
Effect and biomarker of Nivolumab for non–small-cell lung cancer
Wang, L., Zhao, D., Qin, K., Rehman, F. U., & Zhang, X. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109199 · Cited by 42
Common gamma chain cytokines and CD8 T cells in cancer
Shourian, M., Beltra, J., Bourdin, B., & Decaluwe, H. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101307 · Cited by 43
Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells
Martínez-Usatorre, A., Carmona, S. J., Godfroid, C., Maroun, C. Y., Labiano, S., & Romero, P. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00340 · Cited by 41
Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection
Snell, L. M., Xu, W., Abd-Rabbo, D., Boukhaled, G. M., Guo, M., MacLeod, B., Elsaesser, H. J., Hezaveh, K., Alsahafi, N., Lukhele, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01060-7 · Cited by 40
Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer
Xia, L., Guo, L., Kang, J. U., Yang, Y., Yao, Y., Xia, W., Sun, R., Zhang, S., Li, W., Gao, Y.-E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.759217 · Cited by 40
Epigenetics and CD8+ T cell memory*
Montacchiesi, G., & Pace, L. (2021) · Immunological Reviews · doi:10.1111/imr.13057 · Cited by 43
Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control
Perdomo-Celis, F., Passaes, C., Monceaux, V., Volant, S., Boufassa, F., de Truchis, P., Marcou, M., Bourdic, K., Weiss, L., Jung, C., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157549 · Cited by 44
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
Gangaev, A., Rozeman, E. A., Rohaan, M. W., Isaeva, O. I., Philips, D., Patiwael, S., van den Berg, J. H., Ribas, A., Schadendorf, D., Schilling, B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102849118 · Cited by 41
Metabolic dynamics instruct CD8 + T‐cell differentiation and functions
Bevilacqua, A., Li, Z., & Ho, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202149486 · Cited by 41
A variety of ‘exhausted’ T cells in the tumor microenvironment
Nagasaki, J., & Togashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac013 · Cited by 43
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
Chen, M., Ma, P., Zhang, Y., Wang, D., Yu, Z., Fu, Y., Zhao, X., Wang, M., Zhuang, G., & Jing, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007305 · Cited by 43
IFNα-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling
Zheng, C., Wang, J., Zhou, Y. L., Duan, Y., Zheng, R., Xie, Y., Wei, X., Wu, J., Shen, H., Ye, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114088 · Cited by 40
Stimuli-Responsive mRNA Vaccines to Induce Robust CD8 + T Cell Response via ROS-Mediated Innate Immunity Boosting
Dong, L., Deng, X., Li, Y., Zhu, X., Shu, M., Chen, J., Luo, H., An, K., Cheng, M., Zhang, P., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c04331 · Cited by 42
Recent clinical researches and technological development in TIL therapy
Matsueda, S., Chen, L., Li, H., Yao, H. Q., & Yu, F. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03793-4 · Cited by 40
Diverse Roles of Akt in T cells
Abdullah, L., Hills, L. B., Winter, E. B., & Huang, Y. H. (2021) · Immunometabolism · doi:10.20900/immunometab20210007 · Cited by 42
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Relecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 41
How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
Acker, H. H. V., Ma, S., Scolaro, T., Kaech, S. M., & Mazzone, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.006 · Cited by 39
TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
Li, G., Srinivasan, S., Wang, L., Ma, C., Guo, K., Xiao, W., Liao, W., Mishra, S., Zhang, X., Qiu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33768-x · Cited by 40
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice
Mulholland, M., Kritikou, E., Katra, P., Nilsson, J., Björkbacka, H., Lichtman, A. H., Rodríguez, A., & Engelbertsen, D. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.005 · Cited by 39
Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine‐Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles
Wang, T., Zhang, H., Han, Y., Zheng, Q. Y., Liu, H., Han, M., & Li, Z. (2023) · Advanced Science · doi:10.1002/advs.202204961 · Cited by 39
Targeting PGLYRP1 promotes antitumor immunity while inhibiting autoimmune neuroinflammation
Schnell, A., Huang, L., Regan, B. M. L., Singh, V., Vonficht, D., Bollhagen, A., Wang, M., Hou, Y., Bod, L., Sobel, R. A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01645-4 · Cited by 39
Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages
Sun, R., Lei, C., Xu, Z., Gu, X., Huang, L., Chen, L., Tan, Y., Peng, M., Yaddanapudi, K., Siskind, L. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45084-7 · Cited by 43
Stem-like T cells are associated with the pathogenesis of ulcerative colitis in humans
Li, Y., Ramírez-Suástegui, C., Harris, R. J., Castañeda-Castro, F. E., Ascui, G., Pérez-Jeldres, T., Diaz, A., Morong, C., Giles, D. A., Chai, J. N., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01860-7 · Cited by 39
Thermal-responsive activation of engineered bacteria to trigger antitumor immunity post microwave ablation therapy
Wu, Y., Liu, B., Yan, Y., Gong, C., Wang, K., Liu, N., Zhu, Y., Li, M., Wang, C., Yang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54883-x · Cited by 48
Single-cell and spatial transcriptomics integration: new frontiers in tumor microenvironment and cellular communication
Shi, W., Zhang, Z., Xu, X., Tian, Y., Feng, L., Huang, X., Du, Y., & Li, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649468 · Cited by 45
Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma
Bachem, A., Clarke, M. V., Kong, G., Tarasova, I., Dryburgh, L., Kosack, L., Lee, A. R., Newland, L. G. M., Wagner, T., Bawden, E., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.004 · Cited by 46
Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting
Miyahira, A. K., Sharp, A., Ellis, L., Jones, J. C., Kaochar, S., Larman, H. B., Quigley, D. A., Ye, H., Simons, J. W., Pienta, K. J., et al. (2019) · The Prostate · doi:10.1002/pros.23934 · Cited by 40
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade
Hansen, K., Kumar, S., Logronio, K. A., Whelan, S., Qurashi, S., Cheng, H., Drake, A., Tang, M. L., Wall, P., Bernados, D., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02921-8 · Cited by 39
TCF-1 maintains CD8+ T cell stemness in tumor microenvironment
Wen, S., Lu, H., Wang, D., Guo, J., Dai, W., & Wang, Z. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr1120-778r · Cited by 43
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer
Jin, K., Yu, Y., Zeng, H., Liu, Z., You, R., Zhang, H., Liu, C., Su, X., Yan, S. R., Chang, Y., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01725-6 · Cited by 42
The cellular and molecular basis of CD69 function in anti-tumor immunity
Koyama‐Nasu, R., Wang, Y., Hasegawa, I., Endo, Y., Nakayama, T., & Kimura, M. Y. (2022) · International Immunology · doi:10.1093/intimm/dxac024 · Cited by 44
Advancing beyond the twists and turns of T cell exhaustion in cancer
van der Heide, V., Humblin, É., Vaidya, A. B., & Kamphorst, A. O. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4997 · Cited by 41
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng, B., Yu, Q., & Wang, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00894-z · Cited by 43
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 40
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights
Fransen, M. F., van Hall, T., & OSSENDORP, F. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179401 · Cited by 39
Krüppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells
Nah, J., & Seong, R. H. (2022) · Science Advances · doi:10.1126/sciadv.adc9346 · Cited by 40
Id2 epigenetically controls CD8+ T-cell exhaustion by disrupting the assembly of the Tcf3-LSD1 complex
Li, Y., Han, M., Wei, H., Huang, W., Chen, Z., Zhang, T., Qian, M., Lin, J., Nan, G., Sun, X., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01118-6 · Cited by 39
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
Becker, J. C., Stang, A., Schrama, D., & Ugurel, S. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00858-z · Cited by 42
EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lü, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05456-5 · Cited by 38
CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway
Cao, C., Xu, M., Ye, W., Peng, T., Lin, S., Liu, X., Xu, Y., Chu, T., Liu, S., Wu, P., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100659 · Cited by 39
CD4 T cell dysfunction is associated with bacterial recrudescence during chronic tuberculosis
Chang, E., Cavallo, K., & Behar, S. M. (2025) · Nature Communications · doi:10.1038/s41467-025-57819-1 · Cited by 39
Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer
Sanders, T. J., Nabel, C. S., Brouwer, M., Hermant, A. L., Chaible, L. M., Deglasse, J.-P., Rosewick, N., Pabois, A., Cathou, W., Smets, A., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02153-3 · Cited by 44
Extracellular pH modulating injectable gel for enhancing immune checkpoint inhibitor therapy
Jin, H., Choi, D., Ko, M., Kim, D., Lee, Y., Lee, S., Lee, A. Y., Kang, S. G., Kim, S. H., Jung, Y., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.041 · Cited by 38
Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma
Parmar, H. V., Gertz, M. A., Anderson, E. I., Kumar, S. K., & Kourelis, T. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003857 · Cited by 38
Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection
Milner, J. J., Toma, C., Quon, S., Omilusik, K. D., Scharping, N. E., Dey, A., Reina‐Campos, M., Nguyen, H., Getzler, A. J., Diao, H., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20202512 · Cited by 38
T-cell Exhaustion in Organ Transplantation
Angeletti, A., Cantarelli, C., Riella, L. V., Fribourg, M., & Cravedi, P. (2021) · Transplantation · doi:10.1097/tp.0000000000003851 · Cited by 39
Spatial determinants of CD8+ T cell differentiation in cancer
Tooley, K., Escobar, G., & Anderson, A. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.04.003 · Cited by 38
CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy
Ando, S., & Araki, K. (2022) · International Immunology · doi:10.1093/intimm/dxac038 · Cited by 36
Targeting neuropilin-1 abolishes anti-PD-1-upregulated regulatory T cells and synergizes with 4-1BB agonist for liver cancer treatment
Wu, Q., Pan, C., Zhou, Y., Wang, S., Xie, L., Zhou, W., Ding, L., Chen, T., Qian, J., Su, R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000320 · Cited by 37
Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment
Zhou, W., Kawashima, S., Ishino, T., Kawase, K., Ueda, Y., Yamashita, K., Watanabe, T., Kawazu, M., Dansako, H., Suzuki, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113797 · Cited by 38
TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function
Dimitri, A. J., Baxter, A. E., Chen, G. M., Hopkins, C. R., Rouin, G. T., Huang, H., Kong, W., Holliday, C., Wiebking, V., Bartoszek, R. L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp9371 · Cited by 42
CD38 in Advanced Prostate Cancers
Guo, C. W., Crespo, M., Gürel, B., Dolling, D. I., Rekowski, J., Sharp, A., Petremolo, A., Sumanasuriya, S., Rodrigues, D. N., Ferreira, A., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.01.017 · Cited by 36
Harnessing the IL-21-BATF Pathway in the CD8+ T Cell Anti-Tumor Response
Topchyan, P., Xin, G., Chen, Y., Zheng, S., Burns, R., Shen, J., Kasmani, M. Y., Kudek, M. R., Yang, N., & Cui, W. (2021) · Cancers · doi:10.3390/cancers13061263 · Cited by 39
PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion
Hope, J. L., Otero, D. C., Bae, E., Stairiker, C. J., Palete, A. B., Faso, H. A., Lin, M. P., Henriquez, M. L., Roy, S. B., Seo, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112436 · Cited by 39
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
Pirozyan, M. R., McGuire, H. M., Emran, A. A., Tseng, H.-Y., Tiffen, J. C., Lee, J. H., Carlino, M. S., Menzies, A. M., Long, G. V., Scolyer, R. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00372 · Cited by 34
Dynamic regulatory networks of T cell trajectory dissect transcriptional control of T cell state transition
Yan, M., Hu, J. R., Yuan, H., Xu, L., Liao, G., Jiang, Z., Zhu, J., Pang, B., Ping, Y., Zhang, Y., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.10.011 · Cited by 34
Cyclic nucleotide phosphodiesterases as drug targets
Kelly, M. P., Nikolaev, V. O., Gobejishvili, L., Lugnier, C., Heßlinger, C., Nickolaus, P., Kass, D. A., de Vasconcelos, W. P., Fischmeister, R., Brocke, S., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100042 · Cited by 38
Mitochondrial Metabolism in T-Cell Exhaustion
Li, F., Yu, F., Yin, Z., & Wang, Y. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157400 · Cited by 42
The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer
Beumer‐Chuwonpad, A., Taggenbrock, R. L. R. E., Ngo, T. A., & van Gisbergen, K. P. J. M. (2021) · Cells · doi:10.3390/cells10092234 · Cited by 40
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
Lu, M., Xu, J., Ye, Y., Wang, Y., Luo, S., & Gong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723609 · Cited by 36
Functional differences between rodent and human PD-1 linked to evolutionary divergence
Masubuchi, T., Chen, L., Marcel, N., Wen, G. A., Caron, C., Zhang, J., Zhao, Y., Morris, G. P., Chen, X., Hedrick, S. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.ads6295 · Cited by 36
BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells
Romine, K. A., MacPherson, K., Cho, H.-J., Kosaka, Y., Flynn, P., Byrd, K., Coy, J. L., Newman, M., Pandita, R., Loo, C. P., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01808-0 · Cited by 35
The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer
Zhang, J., Lei, F., & Tan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166128 · Cited by 39
YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity
Zhang, H., Luo, X.-J., Yang, W., Wu, Z., Zhao, Z., Pei, X., Zhang, X., Chen, C., Lei, J. H., Shi, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53997-6 · Cited by 37
Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy
Maurer, K., Park, C. Y., Mani, S., Borji, M., Raths, F., Gouin, K. H., Penter, L., Jin, Y., Zhang, J. Y., Shin, C. S., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adr0782 · Cited by 42
Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer
Rivadeneira, D. B., Thosar, S. A., Quann, K., Gunn, W. G., Dean, V. G., Xie, B., Parise, A. M., McGovern, A. C., Spahr, K., Lontos, K., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.08.008 · Cited by 37
Striking a Balance—Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation
Hope, J. L., Stairiker, C. J., Bae, E., Otero, D. C., & Bradley, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01595 · Cited by 38
Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells
Chen, C.-Y., Ueha, S., Ishiwata, Y., Shichino, S., Yokochi, S., Yang, D., Oppenheim, J. J., Ogiwara, H., Deshimaru, S., Kanno, Y., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0265 · Cited by 34
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
Verdon, D. J., & Jenkins, M. R. (2021) · Cancers · doi:10.3390/cancers13164245 · Cited by 36
Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
Llinàs‐Arias, P., Íñiguez-Muñoz, S., McCann, K. E., Voorwerk, L., Orozco, J. I. J., Ensenyat-Méndez, M., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021) · Cancers · doi:10.3390/cancers13164139 · Cited by 36
Facts and Hopes for Immunotherapy in Renal Cell Carcinoma
Yao, C., Zhang, T., Wu, T., & Brugarolas, J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2372 · Cited by 35
Let-7 enhances murine anti-tumor CD8 T cell responses by promoting memory and antagonizing terminal differentiation
Wells, A. C., Hioki, K. A., Angelou, C. C., Lynch, A. C., Liang, X., Ryan, D. J., Thesmar, I., Zhanybekova, S., Žuklys, S., Ullom, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40959-7 · Cited by 35
Learning from the nexus of autoimmunity and cancer
Mangani, D., Yang, D., & Anderson, A. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.022 · Cited by 33
Second near-infrared light-activated semiconducting polymer nanomediators enable three-in-one tumor microenvironment modulation for combination immunotherapy
Li, M., Zhao, M., Zhang, Y., Ding, M., Yu, N., Peng, S., Shi, X., & Li, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101833 · Cited by 34
Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
Pich-Bavastro, C., Yerly, L., Domizio, J. D., Tissot-Renaud, S., Gilliet, M. F., & Kuonen, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0219 · Cited by 35
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies
Wu, J., Bloch, N., Chang, A. Y., Bhavsar, R., Wang, Q., Crawford, A., DiLillo, D. J., Vazzana, K., Mohrs, K., Dudgeon, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101747 · Cited by 36
Transcription factor TCF1 binds to RORγt and orchestrates a regulatory network that determines homeostatic Th17 cell state
Mangani, D., Subramanian, A., Huang, L., Cheng, H., Krovi, S. H., Wu, Y., Yang, D., Moreira, T. G., Escobar, G., Schnell, A., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.017 · Cited by 35
Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies
Gálvez‐Cancino, F., Navarrete, M., Beattie, G., Puccio, S., Conde, E., Foster, K. A., Morris, Y., Sahwangarrom, T., Karagianni, D., Liu, J., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.021 · Cited by 37
Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer
Guo, L., Cao, C., Goswami, S., Huang, X., Ma, L., Guo, Y., Yang, B., Li, T., Chi, Y., Zhang, X., et al. (2020) · Clinical Science · doi:10.1042/cs20191261 · Cited by 33
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies
Balança, C.-C., Scarlata, C., Michelas, M., Devaud, C., Sarradin, V., Franchet, C., Gomez‐Roca, C., Gomez‐Roca, C., Tosolini, M., Heaugwane, D., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0855 · Cited by 39
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 35
PD-1 blockade prevents the progression of oral carcinogenesis
Dong, Y., Wang, Z., Mao, F., Cai, L., Dan, H., Jiang, L., Zeng, X. Y., Li, T., Zhou, Y. J., & Chen, Q. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab035 · Cited by 34
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 36
Active surveillance characterizes human intratumoral T cell exhaustion
You, R., Artichoker, J., Fries, A. C., Edwards, A. W., Combes, A. J., Reeder, G. C., Samad, B., & Krummel, M. F. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144353 · Cited by 35
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
Peri, A., Greenstein, E., Alon, M., Pai, J. A., Dingjan, T., Reich-Zeliger, S., Barnea, E., Barbolin, C., Levy, R., Arnedo-Pac, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci129466 · Cited by 36

Authors: Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., Manos, M., Gjini, E., Kuchroo, J. R., Ishizuka, J. J., Collier, J. L., Griffin, G. K., Maleri, S., Comstock, D. E., Weiss, S. A., Brown, F. D., Panda, A., Zimmer, M. D., Manguso, R. T., Hodi, F. S., Rodig, S. J., Sharpe, A. H., & Haining, W. N.
Affiliations: Broad Institute (US)
Massachusetts General Hospital (US)
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
Corresponding author: Haining, W. Nicholas
ORCID: Miller, Brian C.
Sen, Debattama R.
Al Abosy, Rose
Bi, Kevin
Virkud, Yamini V.
LaFleur, Martin W.
Yates, Kathleen B.
Lako, Ana
Felt, Kristen
Naik, Girish S.
Manos, Michael
Gjini, Evisa
Kuchroo, Juhi R.
Ishizuka, Jeffrey J.
Collier, Jenna L.
Griffin, Gabriel K.
Comstock, Dawn E.
Weiss, Sarah A.
Zimmer, Margaret D.
Manguso, Robert T.
Hodi, F. Stephen
Rodig, Scott J.
Sharpe, Arlene H.
Haining, W. Nicholas
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2019-02-18
Volume: 20
Issue: 3
Pages: 326-336
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/s41590-019-0312-6
PMC: PMC6673650
OpenAlex: W2913558101
Cited by: 2,087
References: 53
Citations by year: 2026: 319 · 2025: 334 · 2024: 358 · 2023: 300 · 2022: 276 · 2021: 269 · 2020: 176 · 2019: 55
FWCI: 81.19
Type: journal article
Language: en
Update notices: correction (2019-10-03)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (KL2TR002542)
National Heart, Lung, and Blood Institute (T32HL007627)
National Cancer Institute (T32CA207021, T32CA009172)
National Institute of General Medical Sciences (T32GM007753)
National Institute of Allergy and Infectious Diseases (R01AI115712, K23AI130408, U19AI133524, P01AI056299)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell exhaustion, CD8+ T cells, PD-1, anti-PD-1 therapy, immune checkpoint blockade, tumor-infiltrating lymphocytes, melanoma, T cell polyfunctionality, chronic viral infection, tumor control
MeSH terms: Animals, Female, Humans, Lymphocytic Choriomeningitis, Lymphocytic choriomeningitis virus, Melanoma, Experimental, Mice, Inbred C57BL, Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Antibodies, Blocking, Mice, Congenic, Cell Line, Tumor, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks